🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — May 16, 2026

The three contracts total $1,363,309,712 in obligations across zero defense awards and three civilian awards. The dominant theme is large-scale civilian IT and infrastructure modernization led by the Department of Veterans Affairs ($502M Oracle award), Department of State ($545M BL Harbert award), and Department of the Treasury ($316M Lancer award). Highest-conviction signal is the bullish 7/10 rating on Lancer Information Solutions' firm-fixed-price Salesforce delivery order with $232M already outlayed. Key risk or watch item is zero outlays to date on the $502M Oracle Health EHRM and $545M BL Harbert contracts despite full obligation.

3 total filings
· daily

High-Value Federal Grants ($5M+) — May 16, 2026

Four civilian contracts totaling $1,379,719,154 were awarded across Department of State, Veterans Affairs, Treasury, and Homeland Security with zero defense-related awards. Dominant themes center on large-scale embassy construction and civilian IT modernization including EHRM licenses, Salesforce services, and maritime communications hardware. The highest-conviction signal is the bullish 7/10 rating on Lancer Information Solutions' $316,242,190 firm-fixed-price delivery order from Treasury Departmental Offices. Key watch item is the $0 outlayed status on the three largest obligations ($544.7M BL Harbert, $502.4M Oracle Health, and $16.4M Lockheed Martin) despite full obligation.

4 total filings
· daily

General Federal Contracts — May 16, 2026

The four contracts total $1,379,719,154 in obligations across a May 2026 snapshot, with a 0/4 defense-related split and all awards going to civilian agencies. The dominant theme is civilian IT services and infrastructure support, led by VA EHRM and Treasury Salesforce work plus a large State Department construction award. Highest-conviction signal is the bullish $316,242,190 firm-fixed-price delivery order to Lancer Information Solutions, LLC for Treasury Departmental Offices. One key risk or watch item is the $0 outlayed to date on the $502M Oracle VA contract and $545M BL Harbert State contract despite full obligation, signaling potential execution or billing delays through 2027-2029.

4 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 15, 2026

Across 50 overnight SEC filings for May 14-15, 2026, Q1 2026 10-Qs dominate (25+ filings) revealing mixed results for micro/small caps: 18/25 showed revenue declines averaging -25% YoY (e.g., Volato -96%, FreeCast -35%) but 15/25 narrowed net losses via 20-40% opEx cuts, highlighting cost discipline amid topline weakness. SPACs (e.g., Spring Valley IV/III, Range Capital) maintained stable Trust Accounts (~$230M avg, +0.5-1% QoQ from interest) but flagged massive liabilities like $425M subscription expense. Positive standouts include regulatory clearances (Methode), debt refinancings (TPG RE $500M facilities), and fund gains (Global Macro +11.7% NAV, Nestor +12.4% capital). Neutral themes: Board changes/appointments (James Hardie, Heartland/Globalstar AGMs with strong votes), investor conferences (USA Comp, Kinder Morgan May 19-27), monthly credit metrics (Synchrony/Capital One), and 13F snapshots showing institutional conviction in REITs/tech (Hyundai $48M Claros, Silver Lake $3.6B). Portfolio-level: Margin resilience (12 cos gross profit up YoY despite rev down), cash infusions from IPOs/financings (Rank One +$21M, NeoVolta equity +$21M), but cash burns persist (avg op cash use $1-5M). Implications: Tactical buys in loss-narrowing turnarounds; caution on high-burn SPACs; monitor conferences for guidance.

33 high priority 17 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 14, 2026

This week's seven FDA approvals in the Biotech Small-Cap stream comprise 1 NME (PEGFILGRASTIM-PCCG by ACCORD BIOPHARMA INC.), 5 biosimilars (LEVETIRACETAM by MYLAN LABS LTD, HYDROCORTISONE SODIUM SUCCINATE by ZYDUS PHARMS, PALIPERIDONE by I3 PHARMS, BRIMONIDINE TARTRATE by MICRO LABS, Unknown by DR REDDYS LABS LTD), and 1 label expansion (DOLUTEGRAVIR by LACHMAN CONSULTANT SERVICES, INC.), overriding the aggregate '7 Other' mix with detailed classifications. No dominant therapeutic area theme, as approvals span neurology/psychiatry (LEVETIRACETAM, PALIPERIDONE), ophthalmology (BRIMONIDINE TARTRATE), HIV (DOLUTEGRAVIR), and oncology supportive care (PEGFILGRASTIM-PCCG). Highest-conviction signal is ACCORD BIOPHARMA INC.'s NME approval for PEGFILGRASTIM-PCCG (ENNUMO), a bullish catalyst with 8/10 strength and materiality, signaling 5-year NCE exclusivity and strong execution for this small-cap entrant. Overall, 2 bullish signals dominate amid 5 neutrals, favoring selective small-cap upside. Key risk/watch item: Biosimilar entries intensify competitive pressure and potential 30-60% revenue erosion for originators over 2-3 years, though originators unnamed.

7 total filings
· daily

Orphan Drug Approvals — May 14, 2026

The FDA approved 3 Other drugs in the Orphan Drug stream from May 14, 2026 to May 14, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 3 Others, generating 3 bullish signals and no bearish or neutral outcomes. Argenx BV dominated with label expansions for EFGARTIGIMOD ALFA (VYVGART) and EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC (VYVGART HYTRULO), representing the highest-conviction signal due to dual approvals underscoring pipeline execution in the orphan space and potential for expanded rare disease access. Merus N.V. also secured a label expansion for ZENOCUTUZUMAB-ZBCO (BIZENGRI), adding to the bullish momentum. No dominant therapeutic area theme emerged from the approvals. Key risk/watch item: All commercial details including peak sales estimates, exclusivity, pricing power, and market position remain NOT_DISCLOSED, necessitating monitoring for post-approval uptake and competitive dynamics.

3 total filings